{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-079500","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.152583+00:00","generated_at":"2026-05-15T23:09:56.589225+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"low","headline":"ACR-368 interim data from registrational-intent arms presented at ESGO for endometrial cancer serous subtype","bullets":["Interim data from ACR-368 Phase 2b registrational-intent trial presented at ESGO Congress on February 27, 2026.","Data focused on endometrial cancer, particularly the serous sub-type.","KOL panel discussed potential of ACR-368 to address unmet need in this patient population.","Company-sponsored webcast with on-site and virtual participation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-079500","json":"https://secwatch.observer/filing/0001193125-26-079500.json","markdown":"https://secwatch.observer/filing/0001193125-26-079500.md","text":"https://secwatch.observer/filing/0001193125-26-079500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526079500/0001193125-26-079500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312526079500/d116670d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:09:56.589225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}